$SAVA News
Last published 8mo ago
- 8mo agoSAVAFLNACassava Sciences Announces Name Change to Filana Therapeutics, Inc.GlobeNewswireNew corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading under "FLNA" effective
- 8mo agoSAVACassava Announces Closure of U.S. Department of Justice InvestigationGlobeNewswireAUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous
- 10mo agoSAVACassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer's Disease in the Journal of Prevention of Alzheimer's DiseaseGlobeNewswireAs previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ studies and confirms
- 12mo agoSAVACassava Reports Q3 2025 Financials Results and Provides Business UpdateGlobeNewswireSimufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board
- 1y agoSAVACassava Sciences Appoints Dawn C. Bir to the Board of DirectorsGlobeNewswireAUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous
- 1y agoSAVACassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireAUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous
- 1y agoSAVACassava Reports Q2 2025 Financials Results and Provides Business UpdateGlobeNewswireFollowing positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experienced neuroscience
- 1y agoSAVACassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical OfficerGlobeNewswireJoseph Hulihan, MD, MSHP, brings substantial clinical development experience advancing novel therapies for TSC-related epilepsy and other neurological disordersClinical study for simufilam in TSC-related epilepsy
- 1y agoSAVACassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related EpilepsyGlobeNewswireStudy in a TSC mouse model further demonstrates simufilam's anti-seizure activityStudy conducted in collaboration with TSC Alliance using a well-accepted Tsc1-knockout modelFirst clinical study for simufilam in
- 1y agoSAVACassava Presents Promising Preclinical Simufilam Data at TSC Alliance MeetingGlobeNewswireData show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data from 1,929 patient Phase 3 program AUSTIN, Texas, June 30, 2025 (GLOBE NEWSWIRE)
- 1y agoSAVACassava Reports Q1 2025 Financials Results, Provides Business UpdateGlobeNewswireLicense agreement and recent leadership appointments position Cassava to advance development of simufilam in TSC-related epilepsy $117.3 Million in Cash and Cash Equivalents at March 31, 2025 AUSTIN, Texas, May 08,
- 1y agoSAVACassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSCGlobeNewswireAs SVP, Neuroscience, Dr. Bordey will lead Cassava's ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline
- 1y agoSAVACassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical DevelopmentGlobeNewswireAUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel, investigational treatments,
- 1y agoSAVACassava Sciences Reports Topline Phase 3 REFOCUS-ALZ DataGlobeNewswireSimufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's diseaseSimufilam continued to demonstrate an overall
- 1y agoSAVACassava Sciences Reports 2024 Financial Results and Provides Business UpdateGlobeNewswireTop-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer's disease, expected late first-quarter/early second-quarter 2025License agreement brings potential in a new therapeutic application for
- 1y agoSAVACassava Sciences Licenses Simufilam Method of Treatment PatentGlobeNewswireCassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with simufilam of seizures related
- 1y agoSAVACassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - SAVAPR NewswireThe Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA...
- 1y agoSAVAShareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVAPR NewswireThe Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA...
- 1y agoSAVAINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CassavaPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the...
- 1y agoSAVACassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SAVAGlobeNewswireNEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ:SAVA). Shareholders who purchased shares of SAVA during the class period
- 1y agoSAVAShareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVAGlobeNewswireNEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ:SAVA). Shareholders who purchased shares of SAVA during the class period
- 1y agoSAVAShareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVAPR NewswireThe Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA...
- 1y agoSAVACassava Sciences Provides a Business UpdateGlobeNewswireTopline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer's disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment including a workforce
- 1y agoSAVACassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVAPR NewswireThe Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA...
- 1y agoSAVAThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVAPR NewswireThe Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA...
- 1y agoSAVADEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CassavaPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the...
- 1y agoSAVACassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary EndpointsGlobeNewswireSimufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease in the ReThink-ALZ Phase 3 study Simufilam continued to
- 1y agoSAVACassava Sciences to Hold Corporate Update on November 25thGlobeNewswireAUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced it will
- 1y agoSAVACassava Sciences Appoints Freda Nassif as Chief Commercial OfficerGlobeNewswireMs. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs Appointment initiates Cassava's commercial readiness strategy as the Company prepares for
- 2y agoSAVACassava Sciences, Inc. (SAVA) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoSAVACassava Sciences Reports Q3 2024 Financial and Operating ResultsGlobeNewswireTop-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024 $149.0 Million in Cash and Cash Equivalents at September 30, 2024. Expected To Support Operations Into 2026 Conference Webcast
- 2y agoSAVACassava Sciences to Report Third Quarter 2024 Results on November 7, 2024GlobeNewswireAUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on
- 2y agoSAVACassava Sciences Resolves SEC InvestigationGlobeNewswireAUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today announced that it has reached a
- 2y agoSAVACassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 TrialsGlobeNewswireAn Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials.The DSMB Recommended Both Phase 3 Trials Continue as Planned,
- 2y agoSAVACassava Sciences Names Rick Barry as Chief Executive OfficerGlobeNewswireAUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today announced it has concluded its search for a Chief Executive Officer
- 2y agoSAVACassava Sciences to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireAUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it has been invited to present at the
- 2y agoSAVACassava Sciences, Inc. (SAVA) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoSAVACassava Sciences Reports Q2 2024 Financial Results and Operational UpdatesGlobeNewswire$207.3 Million in Cash and Cash Equivalents at June 30, 2024.Company in Advanced Discussions to Resolve SEC Investigation. $40 Million Estimated Loss Contingency Recorded in Q2 for Resolution.Conference Webcast Scheduled
- 2y agoSAVACassava Sciences Mourns the Death of Board Member Sanford "Sandy" RobertsonGlobeNewswireAUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today reflected on the passing of long-time board member Sanford Robertson. We are profoundly saddened by the passing of our dear
- 2y agoSAVACassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ETGlobeNewswireAUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on
- 2y agoSAVACassava Sciences Announces Expansion of Open-Label Extension TrialsGlobeNewswireOngoing open-label extension trials of simufilam in Alzheimer's disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on treatment, if they desire,
- 2y agoMDXGSAVASRPTCassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other InitiativesGlobeNewswireRick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) --
- 2y agoSAVACassava Sciences Issues Statement on Former Science AdvisorGlobeNewswireAUSTIN, Texas, June 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), reported it has learned today that a federal grand jury returned an indictment charging Hoau-Yan Wang for allegedly defrauding the
- 2y agoSAVACassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of SimufilamGlobeNewswire$126.3 Million In Total Gross Proceeds from Warrant Distribution.Over 1,900 Patients with Alzheimer's Disease Are Randomized in Phase 3 Trials of Simufilam.Over 735 Patients Have Completed a Phase 3 Trial of Simufilam.
- 2y agoSAVACassava Sciences Announces Over $125 Million Raised from Warrant DistributionGlobeNewswireAUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) (the "Company"), a biotechnology company focused on Alzheimer's disease, today announced total gross proceeds of over $125 million
- 2y agoSAVATomorrow is Last Day to Trade SAVAW Warrants on NASDAQGlobeNewswireEnd-of-day, Thursday, May 2, 2024, Will be the Last and Final Day to Trade SAVAW Warrants on NASDAQ.Monday, May 6, 2024, Will be the Last and Final Day to Cash-Exercise SAVAW Warrants.‘Notice of Guaranteed Delivery' Is
- 2y agoSAVARedemption Date Announced for WarrantsGlobeNewswireMonday, May 6, 2024 is Last and Final Day to Exercise Warrants.Once Redeemed, the Warrants Will Cease to Exist and Have No Value. AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA)
- 2y agoSAVACassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 TrialsGlobeNewswireAn Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as
- 2y agoSAVASHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CassavaPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the...
- 2y agoSAVACassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International ConferenceGlobeNewswireAUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced plans to present a virtual oral